AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free ...
Zacks Investment Research on MSN
Natera files Signatera CDx PMA with FDA for bladder cancer MRD test
Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...
Natera's integration into OncoEMR enhances workflow efficiency, simplifying the ordering process for precision medicine tests in oncology practices. The integration supports timely treatment decisions ...
The test showed sensitivity of nearly 60 percent in the MRD window with specificity of 100 percent in patients who did not receive adjuvant chemotherapy.
Multicenter, Signatera™ Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer Breast cancer is the most common cancer in women worldwide, with ...
Multicenter, Signatera™ Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results